Notice of Results

RNS Number : 6371K

Circassia Pharmaceuticals Plc

12 April 2018

 

Circassia Pharmaceuticals PLC

Notice of Preliminary Results

Oxford, UK - 12 April 2018: Circassia Pharmaceuticals plc (LSE: CIR) will announce its preliminary results for the year ended 31 December 2017 on Tuesday 24 April 2018.

A presentation for analysts will take place at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD at 9.30am.  A webcast of the presentation will be available on the Company's website.

For further information please contact:

FTI Consulting
Mo Noonan	[phone]

About Circassia

Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia sells its novel, market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom and Germany, and in a wide range of other countries through its network of partners. The Company recently established a collaboration with AstraZeneca in the US in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza®, and has the US commercial rights to COPD product Duaklir®.

Circassia's development pipeline includes a range of respiratory medicines. The Company's lead asthma treatment targets substitution of GSK's Flixotide® pMDI and was approved in the UK. Circassia is also developing a direct substitute for Seretide® pMDI, and its pipeline includes a number of inhaled medicines for COPD, including single and combination dose products. For more information on Circassia please visit www.circassia.com.

 

END

 

 

NORGMGMDVMMGRZM